An investment case for maternal and neonatal tetanus elimination

Vaccine. 2020 Feb 24;38(9):2241-2249. doi: 10.1016/j.vaccine.2019.11.052. Epub 2020 Jan 21.

Abstract

Introduction: Globally, 13 countries have yet to eliminate maternal and neonatal tetanus. While efforts have improved access to tetanus toxoid containing vaccines (TTCVs) and increased clean delivery practices, reaching elimination targets (<1 case of neonatal tetanus per 1000 live births per district per year) may require significant resources to reach the remaining high risk and hard-to-reach districts.

Methods: We estimated the cost to achieve maternal and neonatal tetanus elimination (MNTE) in three years in the remaining 13 countries: Afghanistan, Angola, Central African Republic, Democratic Republic of the Congo, Guinea, Mali, Nigeria, Pakistan, Papua New Guinea, Somalia, South Sudan, Sudan, and Yemen. Costs were estimated for: (1) vaccination campaigns using standard TTCVs and TT-Uniject™ targeting women of reproductive age in high risk areas, (2) additional vaccinations delivered to pregnant women at antenatal care (ANC) clinics, (3) clean delivery and umbilical cord care promotion, (4) neonatal tetanus surveillance strengthening, and (5) validation activities. We forecasted the averted mortality to assess the cost-effectiveness of achieving MNTE.

Results: It will cost an estimated US$197.7 million to realize MNTE over three years. These costs include $161.4 million for vaccination campaigns, $6.1 million for routine vaccination during ANC, $23.3 million for promotion of clean delivery practices, $4 million for surveillance, and $3 million for validation of MNTE. Achieving MNTE will avert approximately 70,000 neonatal deaths over ten years of vaccine protection, resulting in approximately 4.4 million life years gained. It will cost $2,900 per death averted and $45 per life year gained.

Conclusion: Maternal and neonatal tetanus can be eliminated with significant financial investment, high prioritization, and strong political will. While substantial costs must be incurred to reach hard-to-reach populations, MNTE should be accomplished as a matter of health equity, and will significantly contribute to reaching the United Nations' Sustainable Development Goals.

Keywords: Cost-effectiveness; Elimination; Maternal child health; Neonatal mortality; Tetanus; Vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Afghanistan
  • Angola
  • Central African Republic
  • Child Health Services / economics
  • Democratic Republic of the Congo
  • Disease Eradication / economics*
  • Female
  • Guinea
  • Humans
  • Infant, Newborn
  • Mali
  • Maternal Health Services / economics
  • Nigeria
  • Pakistan
  • Papua New Guinea
  • Pregnancy
  • Somalia
  • South Sudan
  • Sudan
  • Tetanus Toxoid / economics*
  • Tetanus Toxoid / supply & distribution
  • Tetanus* / economics
  • Tetanus* / prevention & control
  • Yemen

Substances

  • Tetanus Toxoid